Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — J.P. Morgan Healthcare Conference 2013
23 slides from Halozyme Therapeutics's conference presentation, Jan 7, 2013
Slide 1: Thinking Outside the Cell - J.P. Morgan Healthcare Conference
Halozyme Therapeutics, Inc. Thinking Outside the Cell™ J.P. Morgan Healthcare Conference January 10, 2013 Gregory I. Frost, Ph.D. President and Chief Executive Officer Exhibit 99.1
Slide 2: Safe Harbor
2 Safe Harbor All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and all references to financial estimates are based
Slide 3: Company Snapshot
3 PRODUCTS & PIPELINE Hylenex PEGPH20 HTI-501 PARTNERS Roche Pfizer ViroPharma Baxter Intrexon REVENUE MODEL Partnered & Proprietary R&D FOCUS Recombinant Human Enzymes Company Snapshot 3 MANAGEMENT TEAM 11 Product Launches 9 Products Developed 147in San Diego EMPLOYEES
Slide 4: Thinking Outside the Cell = Extracellular Matrix (ECM)
4 Complex matrix of proteins and carbohydrates that surround the cell Composition unique to every organ and disease state Thinking Outside the Cell = Extracellular Matrix (ECM) 4
Slide 5: Company Focus: Harnessing Recombinant Human Enzymes
5 New Routes of Delivery or Improved Efficacy Company Focus Harnessing Recombinant Human Enzymes 5 Modify Specific Components of ECM Proprietary Human Enzymes • Convert biologics from IV administration to SC injection • Reduce number of SC injections • Improve efficacy of existing therapies • Target
Slide 6: Why Halozyme? Diversified Pipeline
6 Why Halozyme? Diversified Pipeline Strong Financial Position Securing Sustained Growth 6
Slide 7: Products and Product Candidates
7 Products and Product Candidates Therapeutic Area Use / Indication Preclinical Phase 1 Phase 2 Phase 3 Filed Approved Proprietary Product Candidates Hylenex recombinant (hyaluronidase human injection) Various Peptide, small molecule, and fluid delivery Analog Insulin-PH20 (pen market) Endocrinology
Slide 8: Partnered Programs Near-Term Growth Engine
8 Partnered Programs Near-Term Growth Engine • Alpha 1 antitrypsin (pre-clinical) • IV to SC • IV to SC • Phase 2b study currently dosing • First 2 exclusive targets for Primary & Specialty Care • Pfizer elected 3rd exclusive target since deal signing • IV to SC or improved dosing frequency UP TO 3
Slide 9: Partnered Programs Yielding Lucrative Revenue Short- and Long-Term
9 Partnered Programs Yielding Lucrative Revenue Short- and Long-Term 9 6 Targets ROYALTY RATES: Commensurate with past deals MabThera $7B Herceptin $6B + 6 additional targets ROYALTY RATES: Mid-single digits HyQ $1.2B ROYALTY RATES: Mid-single digits Cinryze $320M ROYALTY RATES: 10% A1AT – TBD ROYAL
Slide 10: Proprietary Programs Long-Term Value Growth Drivers
10 Novel matrix-remodeling enzyme targeting collagen for aesthetics and scarring HTI-501 (rHuCathepsin-L) Systemically acting enzyme for targeting HA-expressing tumors PEGPH20 (pegylated rHuPH20) FDA approved (150U) for the dispersion and absorption of other injected drugs and fluids Hylenex Recombi
Slide 11: Hylenex on Track for Solid Future
11 Indicated to increase dispersion and absorption of other injected drugs and fluids • Establishing base with hospital and surgery center markets – Regional anesthesia – Hydration and extravasation • Building endocrinology market – Facilitate SC absorption of insulin for patients with diabetes on i
Slide 12: Hyaluronidase for Insulin Pumps
12 6:00 10:00 14:00 18:00 22:00 2:00 6:00 Hyaluronidase for Insulin Pumps A Novel Approach to More Physiologic Insulin Absorption 12 P lasma I n s u li n L e v e ls Pumps Pumps + Hyaluronidase Normal insulin secretion Breakfast Lunch Dinner
Slide 13: Hylenex in Insulin Pumps: Three Steps to Commercial Readiness
13 Additional studies in relevant patient populations Post-Marketing Trials Multiple device options Device Approvals New fill and finish lines Manufacturing Scale Up Hylenex in Insulin Pumps Three Steps to Commercial Readiness Significant contribution to revenue growth by end of 2014 13
Slide 14: PEGPH20 in Pancreatic Cancer: Promising Shift in Treatment Paradigm
14 PEGPH20 in Pancreatic Cancer Promising Shift in Treatment Paradigm Drugs can access tumor CTX + PEGPH20 Channels to tumor opened PEGPH20 Access of drugs to tumor restricted CTX 14
Slide 15: PEGPH20 in Pancreatic Cancer: Translational Imaging Supports MOA
15 PEGPH20 in Pancreatic Cancer Translational Imaging Supports MOA Baseline Day 1 Day 2 End of Cycle 1 Ktrans (min-1) Mean* 0.057 0.147 0.242 0.212 Pre-treatment 24 hrs post-treatment *DCE MRI Imaging Gd contrast agent 3 µg/kg QW dosing Primary tumor 15 Primary tumor
Slide 16: PEGPH20 in Pancreatic Cancer
16 PEGPH20 in Pancreatic Cancer 16
Slide 17: HTI-501 (rHuCAT-L): A Novel Conditionally Active Biologic
17 HTI-501 (rHuCAT-L) A Novel Conditionally Active Biologic 17 Clinical program • Cellulite first target • Phase 1 complete – well tolerated at all doses • Randomized Phase 2 data to be presented 1H 2013 Multiple conditions involve collagen pathologies • Cellulite, keloid scars, Dupuytren’s contract
Slide 18: Why Halozyme? Strong Financial Position
18 Why Halozyme? 18 Diversified Pipeline Strong Financial Position Securing Sustained Growth
Slide 19: Financials: Well Positioned for 2013 and Beyond
19 Financials Well Positioned for 2013 and Beyond 19 2012 2013 2014+ $100M* in cash January 1, 2013 $45-50M 2013 estimated net cash burn Partner Royalties start 2013 Cash flow positive expected as early as 2014 Well-financed to support proprietary product launches and advance pipeline *Includes $30M
Slide 20: Why Halozyme? Securing Sustained Growth
20 Why Halozyme? 20 Diversified Pipeline Strong Financial Position Securing Sustained Growth
Slide 21: Halozyme's Growth Strategy
21 Halozyme’s Growth Strategy High Value Partnerships Buffer Proprietary Spend 21 Proprietary Only Model Partner Only Model Time N e t R e venue Partnered + Proprietary Model N e t R e venue Time N e t R e venue Time
Slide 22: Poised for a Pivotal Year in 2013
22 Advance proprietary programs • Advance clinical trials for PEGPH20 • Present HTI-501 Phase 2 data Secure revenue streams from existing channels • Support EMA filings and launch of Herceptin SC and MabThera SC • Advance insulin pump commercialization Poised for a Pivotal Year in 2013 22 Grow partn
Slide 23: Securing Sustainable Growth
23 Manage business toward positive cash flow Advance proprietary programs Secure revenue streams from existing channels Grow partnerships Securing Sustainable Growth Strategies to Ensure Success 23
Halozyme Therapeutics — J.P. Morgan Healthcare Conference 2013 on 6ix